Hospital Circular 09/2011
Date Issued: 28 April 2011
Distribution: Public Hospitals
Subject: Highly Specialised Drugs Program
Purpose: To advise hospitals of changes to the Highly Specialised Drugs Program, effective 1 May 2011.
Levodopa with Carbidopa
|9743T||Intestinal gel 20mg-5mg per mL, 100mL||56||5||$11,536.00||Duodopa||AB|
Streamlined public hospital authority:
Management of advanced Parkinson disease in a patient with severe disabling motor fluctuations not adequately controlled by oral therapy. (3704)
Treatment must be commenced in a hospital-based movement disorder clinic.
Note: Patients should have adequate cognitive function to manage administration with a portable continuous infusion pump.
A positive clinical response to Duodopa administered via a temporary nasoduodenal tube should be confirmed before a permanent percutaneous endoscopic gastrostomy (PEG) tube is inserted.
Further information on the changes including the full restrictions can be found at Commonwealth/State Highly Specialised Drugs Program Guidelines website or Department of Health and Ageing website.
|9658N||Tablet 500mg (as hydrochloride)||500||2||$2,115.90||Zelitrex||RE|